Wall Street Zen Upgrades Myriad Genetics (NASDAQ:MYGN) to "Hold"

Wall Street Zen Upgrades Myriad Genetics (NASDAQ:MYGN) to "Hold"

Wall Street Zen raised shares of Myriad Genetics from a "sell" rating to a "hold" rating in a research report on Saturday.

Myriad Genetics (NASDAQ:MYGN) Stock Gets Price Target Bump from Leerink Partners

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price increased by stock analysts at Leerink Partners from $5.00 to $8.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “market perform” rating on the stock. Leerink Partners‘s target price would indicate a potential upside of 35.14% […]